Literature DB >> 3090490

Fetal liver ultrasound measurements in isoimmunized pregnancies.

A M Vintzileos, W A Campbell, E Storlazzi, M H Mirochnick, D T Escoto, D J Nochimson.   

Abstract

Sixteen isoimmunized pregnancies at risk for erythroblastosis fetalis were managed by serial amniocenteses for bilirubin delta optical density at 450 nm (delta OD450). Before amniocentesis each fetus was evaluated ultrasonically and the fetal liver size, the abdominal circumference, and the umbilical vein diameter, in both the fetal liver and the umbilical cord, were measured. The ultrasonically determined fetal liver size, as well as its growth rate, was found to be greater than normal during the last two weeks before intervention (intrauterine transfusion or delivery) in all eight fetuses with severe hemolytic disease. The umbilical vein diameter in the fetal liver was above normal in only one fetus, whereas the abdominal circumference was increased in only three of the eight severely affected fetuses. These data suggest that serial fetal liver ultrasound measurements may be useful as an adjunct to amniotic fluid analysis to predict the severely affected fetus in need of prompt intervention (intrauterine transfusion or delivery).

Entities:  

Mesh:

Year:  1986        PMID: 3090490

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  3 in total

Review 1.  Haemolytic disease of newborn.

Authors:  A Narang; N Jain
Journal:  Indian J Pediatr       Date:  2001-02       Impact factor: 1.967

Review 2.  Foetal haemodynamic response to anaemia.

Authors:  Keooudone Thammavong; Suchaya Luewan; Phudit Jatavan; Theera Tongsong
Journal:  ESC Heart Fail       Date:  2020-09-10

3.  Morphometric study of the diaphragmatic surface of the liver in the human fetus.

Authors:  Monika Paruszewska-Achtel; Małgorzata Dombek; Mateusz Badura; Gabriela Elminowska-Wenda; Maria Dąbrowska; Magdalena Grzonkowska; Mariusz Baumgart; Anna Szpinda-Barczyńska; Michał Szpinda
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.